7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals RYTM, offering a diverse range of perspectives from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.71, with a high estimate of $76.00 and a low estimate of $64.00. This upward trend is evident, with the current average reflecting a 3.27% increase from the previous average price target of $67.50.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Rhythm Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Rhythm Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rhythm Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Rhythm Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Rhythm Pharmaceuticals analyst ratings.

Unveiling the Story Behind Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

A Deep Dive into Rhythm Pharmaceuticals's Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, Rhythm Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 47.76% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Rhythm Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -131.25%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Rhythm Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -172.64%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Rhythm Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.71%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.36, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: Simplified

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.